Ticker brief
AZN ASTRAZENECA PLC
Consumer, Non-cyclical · Pharmaceuticals
last close
$171.49
1 day
-0.6%
14 days
+7.7%
mkt cap
$302.7B
signals 14d
37
authors 14d
27
crowd 14d
-0.2σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 35% rich · 100 pctile own 1y | IV/HV 1.36× |
| Skew — 25Δ RR 30d | -0.010 80 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.04 elevated | 5-session Δ +0.00 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2024-11-06 (z=3.4) |
| Next earnings | 2026-10-30 (proj) | in 4d |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.40 (−1 bearish … +1 bullish)
Who spoke27
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @fwpharma | B | -1.91 | 4 | +0.10 |
| @KontraInvest | A | +1.21 | 3 | -0.60 |
| @semodough | C | -1.06 | 2 | +0.38 |
| @robertojirusta | C | -0.38 | 2 | +0.30 |
| @bioinvestor24 | A | -0.87 | 2 | -0.30 |
| @investseekers | B | +0.02 | 2 | +0.10 |
| @CHItrader | B | -0.22 | 2 | -0.05 |
| @BlueJay87476298 | B | -0.85 | 1 | +0.10 |
| @faststocknewss | C | +1.70 | 1 | +0.20 |
| @tenet_research | C | -1.23 | 1 | +0.30 |
| @WOLF_Financial | C | -3.03 | 1 | +0.25 |
| @CNBC | C | +0.31 | 1 | +0.20 |
| @BiopharmIQ | B | · | 1 | +0.25 |
| @IngJuanPa7 | B | +0.98 | 1 | +0.30 |
| @ttvresearch | C | +1.59 | 1 | -0.10 |
| @TalkMarkets | C | · | 1 | -0.45 |
| @PersimmonTI | A | +0.79 | 1 | +0.35 |
| @Mariusz_Invest | C | -0.49 | 1 | +0.00 |
| @PrismMarketView | C | · | 1 | -0.50 |
| @GetPursa | C | +0.10 | 1 | -0.50 |
| @proactive_x | C | -1.13 | 1 | +0.30 |
| @OpenOutcrier | C | · | 1 | +0.40 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @everytimeicash | B | -0.87 | 1 | +0.40 |
| @SevenParr | C | -3.25 | 1 | +0.65 |
Recent signals30of 37 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @investseekers | +0.40 | CHMP recommends expanded indications and marketing authorization for named medicines. | +3.7% | tweet ↗ |
| 2026-10-15 | @BarbarianCap | +0.25 | AstraZeneca struck an AI drug-discovery agreement with Insitro worth up to $1.5 billion. | +2.9% | tweet ↗ |
| 2026-10-15 | @beach_trades | +0.15 | SOPHiA and Myriad announced a PrGIS collaboration supporting precision oncology with AstraZeneca. | +2.9% | tweet ↗ |
| 2026-10-15 | @SevenParr | +0.65 | Cites continuing accumulation in the $160s at prior quarterly resistance turned support after a 25% correction. | +2.9% | tweet ↗ |
| 2026-10-15 | @bioinvestor24 | -0.10 | Compares upcoming pan-RAS datasets and says response durability will determine competitive positioning. | +2.9% | tweet ↗ |
| 2026-10-15 | @fwpharma | +0.30 | AstraZeneca and insitro entered a $1.5B cardiometabolic drug-discovery deal. | +2.9% | tweet ↗ |
| 2026-10-14 | @everytimeicash | +0.40 | Identifies a defensive rotation into pharma and value retail. | +5.8% | tweet ↗ |
| 2026-10-14 | @OptionsFlowBoss | +0.35 | Reports unusual bullish options-volume multiples near the closing bell. | +5.8% | tweet ↗ |
| 2026-10-13 | @OpenOutcrier | +0.40 | Lists equity upgrades; output is capped at the first six tickers. | +10.1% | tweet ↗ |
| 2026-10-12 | @proactive_x | +0.30 | Citi estimates efzimfotase alfa could reach $4.4 billion in peak sales. | +8.3% | tweet ↗ |
| 2026-10-12 | @GetPursa | -0.50 | AstraZeneca's Phase 3 HICKORY trial missed its primary endpoint. | +8.3% | tweet ↗ |
| 2026-10-12 | @PrismMarketView | -0.50 | Summarizes a Phase 3 miss, FDA-path efforts, an approval and another developer's oral program. | +8.3% | tweet ↗ |
| 2026-10-12 | @CHItrader | -0.50 | AstraZeneca's Phase 3 HICKORY trial failed its primary endpoint. | +8.3% | tweet ↗ |
| 2026-10-12 | @fwpharma | -0.35 | AstraZeneca disclosed additional detail on an earlier Phase III trial failure. | +8.3% | tweet ↗ |
| 2026-10-11 | @Mariusz_Invest | +0.00 | Compares Nvidia's $5.5T valuation with the £2.5T FTSE 100 and several major UK constituents. | +7.7% | tweet ↗ |
| 2026-10-11 | @PersimmonTI | +0.35 | Frames approaching patent cliffs as a driver of pharmaceutical M&A activity. | +7.7% | tweet ↗ |
| 2026-10-09 | @KontraInvest | -0.55 | Argues AstraZeneca will not take obesity-market share from Novo. | +7.7% | tweet ↗ |
| 2026-10-09 | @KontraInvest | -0.60 | Says a possible 2029-30 US launch leaves little hope for AstraZeneca. | +7.7% | tweet ↗ |
| 2026-10-09 | @robertojirusta | +0.35 | AstraZeneca is reportedly on track to meet its 2030 revenue target. | +7.7% | tweet ↗ |
| 2026-10-09 | @CHItrader | +0.40 | AstraZeneca says it remains on track for its 2030 revenue target. | +7.7% | tweet ↗ |
| 2026-10-08 | @KontraInvest | -0.65 | Clinical benchmarking finds AZN's oral GLP-1 late and undifferentiated, with little threat to NVO or LLY. | +8.0% | tweet ↗ |
| 2026-10-07 | @fwpharma | +0.25 | Reports AstraZeneca opened a research-and-development hub in Massachusetts worth more than $1B. | +7.1% | tweet ↗ |
| 2026-10-07 | @investseekers | -0.20 | Reports an AI clinical-trial model's predictions, track record and potential sector implications. | +7.1% | tweet ↗ |
| 2026-10-06 | @bioinvestor24 | -0.50 | Argues AZN's preclinical obesity work will have no meaningful impact. | +8.1% | tweet ↗ |
| 2026-10-06 | @TalkMarkets | -0.45 | Reports AZN fading under China tariff warnings and hawkish Bank of England remarks. | +8.1% | tweet ↗ |
| 2026-10-06 | @ttvresearch | -0.10 | Charts public companies investigated or settled with by the Texas attorney general; capped at six. | +8.1% | tweet ↗ |
| 2026-10-06 | @IngJuanPa7 | +0.30 | Frames roughly $500B of US pharmaceutical investment as tariff mitigation and supply-chain reshoring. | +8.1% | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | +0.25 | Weekly biotech roundup highlights patent, investment, clinical-data and analyst developments. | +9.6% | tweet ↗ |
| 2026-10-05 | @CNBC | +0.20 | AstraZeneca's CEO says a Summit drug could underpin next-generation cancer combinations after a $2 billion investment. | +9.6% | tweet ↗ |
| 2026-10-05 | @WOLF_Financial | +0.25 | Reports AZN's $1B investment, workforce expansion, and new R&D center. | +9.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.